3 Ominous Reasons to Avoid This Biotech Pioneer
Investing in biotech companies can be risky. Biotechs are often a corporation wrapped around a hypothesis. If the hypothesis works out, riches can follow. But if not, the company can go bankrupt or be sold for pennies after years of frustration.
CRISPR gene editing -- that's short for "clustered regularly interspaced short palindromic repeats" -- has garnered a lot of attention in the past decade. There has also been a ton of investment. CRISPR won a Nobel prize and has been called the discovery of the century. But one of the early pioneers in the field has warning signs that I believe should keep it off investors' radars. Here are three reasons I wouldn't invest in Editas Medicine (NASDAQ: EDIT).
Image source: Getty mages.
Source Fool.com
